Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer

DOI: 10.1016/j.jchromb.2021.122752
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1175, 122752.

#	Paper	IF	Citations
13	Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. *Biomedical Chromatography*, **2021**, 35, e5224	1.7	0
12	Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction. *Journal of Pharmaceutical and Biomedical Analysis*, **2021**, 204, 114276	3.5	4
11	Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.. *Journal of Pharmaceutical and Biomedical Analysis*, **2021**, 212, 114517	3.5	1
10	Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. *Frontiers in Pharmacology*, 13,	5.6	0
9	Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS. *Molecules*, **2022**, 27, 4474	4.8	1
8	A rapid and sensitive UPLC-MS/MS method for determination of anlotinib in plasma and dried blood spots: Method development, validation and clinical application.		0
7	Establishment and validation of a LC‐MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoring.		0
6	A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of thirty-nine tyrosine kinase inhibitors in human plasma. **2023**, 224, 115159		0
5	Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay.		0
4	Simultaneous online SPE-HPLC-MS/MS quantification of gefitinib, osimertinib and icotinib in dried plasma spots: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. **2023**, 115275		0
3	Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. **2023**, 669, 115115		0
2	Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer. 13,		0
1	Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Non‐Small Cell Lung Cancer. **2023**,		0